dc.contributor.author | Blazeby, JM | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Aaronson, NK | |
dc.contributor.author | Lloyd, L | |
dc.contributor.author | Waters, R | |
dc.contributor.author | Kelly, JD | |
dc.contributor.author | Fayers, P | |
dc.date.accessioned | 2020-08-06T14:52:45Z | |
dc.date.issued | 2014-12-01 | |
dc.identifier.citation | European urology, 2014, 66 (6), pp. 1148 - 1156 | |
dc.identifier.issn | 0302-2838 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3918 | |
dc.identifier.eissn | 1873-7560 | |
dc.identifier.doi | 10.1016/j.eururo.2014.02.034 | |
dc.description.abstract | BACKGROUND: Well-developed and well-tested patient-reported outcome measures for non-muscle-invasive bladder cancer (NMIBC) are required. OBJECTIVE: To test and adapt the scale structure and explore the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire for NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 433 patients in the Bladder COX-2 Inhibition Trial (BOXIT) completed the EORTC QLQ-C30 and NMIBC questionnaires. BOXIT is evaluating the addition of celecoxib to standard treatment in high- and intermediate-risk NMIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multitrait scaling investigated and adapted the questionnaire scale structure and evaluated the reliability and validity of the revised scales, as well as responsiveness to change. RESULTS AND LIMITATIONS: A total of 410 patients (94.7%) (79.3% men, 74.6% high risk) returned baseline forms, and the questionnaire response rate was 88.2%. Multitrait scaling confirmed six scales and five single items. Scales and items demonstrated significant differences between patients with good and poor performance status scores (p<0.001). Men reported better sexual function than women (p<0.001). Scale and single-item module scores were not highly correlated with QLQ-C30 scores (evidence of discriminant validity), and the module was responsive to changes in health over time. International and test-retest data are required. CONCLUSIONS: This study demonstrates the evidence-driven adapted scale structure and psychometric data of the EORTC QLQ-NMIBC24 module to use in clinical trials of patients with high- or intermediate-risk bladder cancer. | |
dc.format | Print-Electronic | |
dc.format.extent | 1148 - 1156 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasm Invasiveness | |
dc.subject | Fever | |
dc.subject | Combined Modality Therapy | |
dc.subject | Reproducibility of Results | |
dc.subject | Sexuality | |
dc.subject | Anxiety | |
dc.subject | Psychometrics | |
dc.subject | Sex Factors | |
dc.subject | Health Status | |
dc.subject | Quality of Life | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Cyclooxygenase 2 Inhibitors | |
dc.subject | Urinary Bladder Neoplasms | |
dc.subject | Social Participation | |
dc.subject | Lower Urinary Tract Symptoms | |
dc.subject | Patient Outcome Assessment | |
dc.subject | Surveys and Questionnaires | |
dc.subject | Celecoxib | |
dc.title | Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2014-02-13 | |
rioxxterms.versionofrecord | 10.1016/j.eururo.2014.02.034 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2014-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European urology | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.publication-status | Published | |
pubs.volume | 66 | |
pubs.embargo.terms | Not known | |
icr.researchteam | ICR-CTSU Urology and Head and Neck Trials Team | |
dc.contributor.icrauthor | Hall, Emma | |